Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent

L. De Marco, S. S. Shapiro

Research output: Contribution to journalArticlepeer-review


Human Factor VIII desialylated by treatment with Vibrio cholerae neuraminidase (ASVIII) aggregates human platelets in the absence of ristocetin in platelet-rich plasma and, to a lesser extent, in washed platelet suspensions. Aggregation is accompanied by thromboxane formation and is completely inhibited by EDTA. Aspirin blocks the second phase of aggregation and abolishes thromboxane production. Subaggregating doses of ASVIII and of either ADP, epinephrine, or collagen produce prompt and complete platelet aggregation. Bernard-Soulier syndrome platelets either did not aggregate with ASVIII (two cases) or showed markedly decreased aggregation (one case). Factor VIII complex was prepared from the plasma of two patients with variant von Willebrand's disease (sialic acid content 142 and 75 nmol/mg, respectively); neither protein generated platelet-aggregating activity upon desialylation. [ 3H]ASVIII binds rapidly to platelets at 37°C, while tritiated, fully sialylated factor VIII binds to a negligible extent. As little as 1-2 μg ASVIII bound/10 9 platelets is capable of inducing platelet aggregation. ASVIII may be a useful tool for investigating platelet-Factor VIII interactions in the absence of ristocetin. Furthermore, desialylated Factor VIII might play a physiologic role in Factor VIII-mediated platelet reactions in vivo.

Original languageEnglish
Pages (from-to)321-328
Number of pages8
JournalJournal of Clinical Investigation
Issue number2
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent'. Together they form a unique fingerprint.

Cite this